Answers are grounded in this paper and cite their sources.
Observational analysis indicates ribociclib may increase hepatotoxicity risk in breast cancer patients, suggesting monitoring is needed for better outcomes.
Ribociclib is associated with an increased risk of hepatotoxicity, with the potential for grade 3-4 in a small number of patients. Our analysis suggested a potential association between grade 3-4 hepatotoxicity and reduced OS, warranting further investigation. Regular monitoring of liver function tests during ribociclib treatment may help clinicians identify high-risk patients requiring closer follow-up.
No takes yet. Share an insight, caveat, or question.
Eroğlu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: